These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 22578156)

  • 1. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
    Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
    BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score.
    Gakis G; Todenhöfer T; Renninger M; Schilling D; Sievert KD; Schwentner C; Stenzl A
    BJU Int; 2011 Dec; 108(11):1800-5. PubMed ID: 21507193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.
    Moschini M; Suardi N; Pellucchi F; Rocchini L; La Croce G; Capitanio U; Briganti A; Damiano R; Montorsi F; Colombo R
    Anticancer Res; 2014 Jun; 34(6):3225-30. PubMed ID: 24922698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
    Rink M; Lee DJ; Kent M; Xylinas E; Fritsche HM; Babjuk M; Brisuda A; Hansen J; Green DA; Aziz A; Cha EK; Novara G; Chun FK; Lotan Y; Bastian PJ; Tilki D; Gontero P; Pycha A; Baniel J; Mano R; Ficarra V; Trinh QD; Tagawa ST; Karakiewicz PI; Scherr DS; Sjoberg DD; Shariat SF;
    BJU Int; 2013 Mar; 111(3 Pt B):E30-6. PubMed ID: 22938654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy.
    Gondo T; Nakashima J; Ohno Y; Choichiro O; Horiguchi Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Urology; 2012 May; 79(5):1085-91. PubMed ID: 22446338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy.
    Sejima T; Morizane S; Yao A; Isoyama T; Saito M; Amisaki T; Koumi T; Takenaka A
    Int J Urol; 2014 Jan; 21(1):52-7. PubMed ID: 23711293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy.
    Bruins HM; Wopat R; Mitra AP; Cai J; Miranda G; Skinner EC; Daneshmand S
    BJU Int; 2013 Mar; 111(3 Pt B):E37-42. PubMed ID: 22974410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer.
    Eisenberg MS; Boorjian SA; Cheville JC; Thompson RH; Thapa P; Kaushik D; Frank I
    J Urol; 2013 Dec; 190(6):2005-10. PubMed ID: 23770147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.
    Mitra AP; Quinn DI; Dorff TB; Skinner EC; Schuckman AK; Miranda G; Gill IS; Daneshmand S
    BJU Int; 2012 Mar; 109(6):846-54. PubMed ID: 21812902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome.
    Jokisch JF; Grimm T; Buchner A; Kretschmer A; Weinhold P; Stief CG; Karl A; Schulz GB
    Urol Int; 2020; 104(1-2):36-41. PubMed ID: 31242481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does patient age affect survival after radical cystectomy?
    Horovitz D; Turker P; Bostrom PJ; Mirtti T; Nurmi M; Kuk C; Kulkarni G; Fleshner NE; Finelli A; Jewett MA; Zlotta AR
    BJU Int; 2012 Dec; 110(11 Pt B):E486-93. PubMed ID: 22551360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
    Mitra AP; Skinner EC; Miranda G; Daneshmand S
    BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Bolenz C; Gilfrich C; Otto W; Trojan L; Herrmann E; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    J Urol; 2012 Apr; 187(4):1210-4. PubMed ID: 22335861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A; English S; Kauffman EC; Din R; Khan A; Syed JR; Sztorc J; Mehedint D; Sharif M; Shi Y; Wilding G; Guru KA
    BJU Int; 2014 Aug; 114(2):253-60. PubMed ID: 24119175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
    Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
    J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.